BIBLIOGRAPHY
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
MAGNUS INGELMAN SUNDBERG
1992-2014
Bühler, R., Lindros, K. O., Nordling, Å., Johansson, I. and Ingelman Sundberg, M.:
Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur J
Biochem, 1992, 204: 407-412.
Ronis, M. J. J., Thomas, P. E., Ingelman Sundberg, M., Badger, T. M. and Lumpkin,
C. K.: The microsomal monooxygenase system of regenerating liver: An
examination of the role of estradiol in the demasculinization of drug metabolism
produced by 2/3 partial hepatectomy. Biochem. Pharmacol, 1992, 43: 567-573.
Takahashi, H., Johansson, I., French, S. W. and Ingelman-Sundberg, M.:Effects of
dietary fat composition on activities of the microsomal ethanol oxidizing system
and ethanol inducible cytochrome P450 in the liver of rats chronically fed ethanol.
Pharmacol. Toxicol., 1992, 70: 347-352.
Cronholm, T., Norsten Höög, C., Ekström, G., Handler, J., Thurman, R. G. and
Ingelman Sundberg, M.: Oxidoreduction of butanol in deer mice (Peromyscus
maniculatus) lacking hepatic cytosolic alcohol dehydrogenase. Eur J Biochem,
1992, 204: 353-358.
Johansson, I., Yue, Q.Y., Dahl, M-L., Heim, M., Bertilsson, L., Meyer, U.A., Sjöqvist,
F. and Ingelman-Sundberg, M.: Genetic analysis of the interethnic difference
between Chinese and Caucasians in the polymorphic metabolism of debrisoquine
and codeine. Eur J Clin Pharmacol 1991, 40: 553-556.
Dahl, M.-L., Johansson, I., Porsmyr-Palmertz, M., Ingelman-Sundberg, M. and
Sjöqvist, F.: Analysis of the CYP2D6 gene in relation to debrisoquine and
desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther, 1992,
52: 12-17.
Shan, X., Aw, T.Y., Smith, E.R., Ingelman-Sundberg, M., Mannervik, B., Yanagi, T.
and Jones, D.P.: Effect of chronic hypoxia on detoxication enzymes in rat liver.
Biochem Pharmacol 1992, 43: 2421-2426.
Ingelman-Sundberg, M., and Ekström, G.: Multiple roles of cytochromeP450 in
lipid peroxidation. in "Biological Free Radical Reactions and Antioxidants"
(Cadenas, E, Ed), Cleup University Publisher, 1992, 43-47.
French, S.W., Wong, K., Jui, L., Albano, E., Hagbjörk, A.-L. and Ingelman-Sundberg,
M.: Effect of ethanol on cytochrome P450 (CYP2E1), lipid peroxidation and serum
protein adduct formation in relation to liver pathology pathogenesis. Exp Mol
Pathol, 1993, 58: 61-75.
Kobusch, A.-B., Schrenk, D., Gans, G., Münzel, P., Werringloer, J., IngelmanSundberg, M. and Bock, K.B.: Immunochemical localization and functional
characterization of cytochrome P-450IIE1 in rat hepatocyte foci and nodules.
Carcinogenesis, 1992, 12: 2353-2356.
Mendez, C.F., Hansson, A., Skoglund, G., Ingelman-Sundberg, M. Aperia, A.:
Protein kinase C activity in rat renal proximal tubule cells. Acta Physiol Scand.
1992, 146: 135-140.
Schrenk, D., Ingelman-Sundberg, M. and Bock, K.W.: Influence of P4502E1
induction on benzene metabolism in rat hepatocytes and on biliary metabolite
excretion, Drug Met Disp, 1992, 20: 137-141.
1
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Ekström, G., Cronholm, T., Norsten-Höög, C. and Ingelman-Sundberg, M:
Dehydrogenase-dependent metabolism of alcohols in gastric mucosa of deer mice
lacking hepatic alcohol dehydrogenase., Biochem Pharmacol, 1993, 45: 1989-1993.
Eliasson, E., Mkrtchian S, and Ingelman-Sundberg, M.: Hormone- and substrate
regulated intracellular degradation of cytochrome P450 (2E1) involving MgATPactivated rapid proteolysis in the endoplasmic reticulum membranes J. Biol. Chem.
1992, 267: 15765-15769.
Eliasson, E. Mkrtchian, S, Halpert, J. and Ingelman-Sundberg, M.: Substrateregulated cAMP-dependent phosphorylation, denaturation and degradation of
glucocorticoid-inducible rat liver cytochrome P450 3A1, J. Biol. Chem, 1994,
269:18378-18383.
Persson, I., Johansson, I., Bergling, H., Dahl, M.-L., Högberg, J., Rannug, A. and
Ingelman-Sundberg, M.: Genetic polymorphism of CYP2E1 in a Swedish
population. Relationship to the occurrence of lung cancer. FEBS lett. 1993, 319:
207-211.
Johansson, I. Oscarson, M., Yue, Q Y, Bertilsson, L., Sjöqvist, F., and IngelmanSundberg, M.: Genetic analysis of the Chinese CYP2D locus. Characterization of
variant CYP2D6 genes present in subjects with diminished capacity for
debrisoquine hydroxylation. Mol Pharmacol 1994, 46: 452-459,.
Hansson, T., von Bahr, C., Marklund, M., Svensson, J. O., Ingelman Sundberg, M.
and Lundström, J.: Different regioselectivity in the hydroxylation of the
antidepressant desmethylimipramine between rat brain and liver. Pharmacol &
Toxicol, 1993, 71: 416-420.
Hu, Y, Mishin, V., Johansson, I., von Bahr, C., Cross, C., Ronis, M.J.J., Badger, T.M.
and Ingelman-Sundberg, M.: Chlormethiazole as an efficient inhibitor of
cytochrome P450 2E1 expression in rat liver. J Pharm Exp Ther, 1994, 269:12861291.
Johansson, I., Bertilsson, L., Dahl, M-L, Sjöqvist, F and Ingelman-Sundberg, M.
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a
cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci (USA), 1993,
90: 11825-11829. Commentary by Urs Meyer in Proc Natl Acad Sci (USA) 1994, 91:
1983-1984.
Ingelman-Sundberg, M., Johansson, I., Persson, I., Lundqvist, E. and Dahl. M.-L.:
Genetic polymorphisms of cytochromes P450: Interethnic differences and
relationship to incidence of lung cancer Pharmacogenetics 1992, 2: 264-271.
(invited).
Bertilsson, L. Meese, C.O., Yue, Q.Y., Dahl. M.-L., Eichelbaum, M., IngelmanSundberg, M., Johansson, I., Säwe, J. and Sjöqvist, F.: Quinidine inhibition of
debrisiquine on the S(+)-4- and 7-hydroxylations in Chinese of different CYP2D
genotypes. Pharmacogenetics, 1993, 3: 94-100.
Dahl, M.-L., Iselius, L., Alm, A., Svensson, J.-O., Johansson, I., Ingelman-Sundberg,
M. and Sjöqvist, F.: Polymorphic 2-hydroxylation of desipramine - a population and
family study. Eur J Clin Pharmacol, 1993, 44: 445-450.
Houde, M., Bracke, M., Skoglund, G., Ingelman-Sundberg, M., Masure, S., van
Damme, J. and Opdenakker, G: Differential regulation of gelatinase B and tissue2
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
type plasminogen activator expression in human Bowes melanoma cells. Int J
Cancer, 1993, 53: 395-400.
Badger, T.M., Ronis, M.J.J., Lumpkin, C.K., Shahare, M., Irby, D., Huang, J.,
Mercado, C., Valentine, C.R., Thomas, P., Ingelman-Sundberg, M. and Crough, J.:
Effects of chronic ethanol on growth hormone secretion and hepatic cytochrome
P450 isozymes of the rat, J Pharm Exp Ther, 1993, 264: 438-447.
Ronis, M.J.J., Crough, J., Mercado, C., Irby, D., Valentine, C., Lumpkin, C.K.,
Ingelman-Sundberg, M. and Badger, T.M.: Cytochrome P450 CYP2E1 induction
during alcohol exposure occurs by a two step mechanism associated with blood
alcohol concentrations in rats, J Pharm Exp Ther, 1993, 264: 944-950.
Bertilsson, L., Dahl, M-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson I.,
Lundqvist, E. and Ingelman-Sundberg, M. : Molecular basis for rational
megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993, 341: 63.
Longo, V. and Ingelman-Sundberg, M.: Acetone-dependent regulation of
cytochromes P450 2E1 and P4502B1 in rat nasal mucosa. Biochem Pharmacol,
1993, 46: 1945-1951.
Morimoto, M., Hagbjörk, A.-L., Nanji, A.A., Ingelman-Sundberg, M., Lindros,K.O.,
Albano, E., and French, S.W.: Role of cytochrome P450 2E1 in alcoholic liver
disease pathogenesis. Alcohol, 1993, 10: 459-464.
Ingelman-Sundberg, M., Johansson, I, Hu, Y., Terelius, Y., Eliasson, E., Clot, P., and
Albano, E.: Ethanol-inducible cytochrome P4502E1: Genetic polymorphism,
regulation and possible role in the etiology of alcohol-induced liver disease.
Alcohol, 1993, 10: 447-452. (invited)
Dahl, M.-L., Bertilsson, L., Ingelman-Sundberg, M., Johansson, I., Lundqvist, E and
Sjöqvist, F.: Molecular basis of drug oxidation polymorphism. Nord Psykiatrisk
Tidsskrift, suppl 30 1993, 27-31.
Albano, E., Comoglio, A., Clot, P., Iannone, A., Tomasi, A. and Ingelman-Sundberg,
M.: Activation of alkylhydrazines to free radical intermediates by ethanol-inducible
cytochrome P-4502E1 (CYP2E1). Biochim Biophys Acta, 1995, 1243: 414-420.
Badger, T.M., Ronis, M.J.J., Ingelman-Sundberg, M. and Hakkak, R.: Pulsatile blood
alcohol and CYP2E1 induction during chronic alcohol infusions in rats. Alcohol,
1993, 10: 453-458.
Muntane, J., Longo, V., Mitjavila, T., Gervasi, P.G., and Ingelman-Sundberg, M.:
Effect of carrageenan-induced granuloma on the apoprotein content and activity
of cytochrome P450 isozymes in liver and nasal mucosa in rats. Inflammation,
1995, 19: 143-156,.
Albano, E., Tomasi, A. and Ingelman-Sundberg, M.: ESR Spin trapping of alcoholderived radicals in microsomes and reconstituted systems by electron spin
resonance, Meth Enzymol 1994, 233: 117-127. (invited)
Morimoto, M., Zern, M.A., Hagbjörk, A.L., Ingelman-Sundberg, M., and French,
S.W. Fish oil, alcohol, and liver pathology: Role of cytochrome P450 2E1. Proc Soc
Exp Biol Med 1994, 207: 197-205.
Alexandrie, A.K., Ingelman-Sundberg, M., Seidegård, J., Tornling, G., and Rannug,
A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and
3
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
GSTM1: A study on host factors in relation to age at onset, gender and histological
cancer types. Carcinogenesis 1994, 15:1785-1790.
Ronis, M.J.J., Ingelman-Sundberg, M., and Badger, T.M. Induction, suppression and
inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and
bobwhite quail (Colinus virginianus) by ergosterol biosynthesis inhibiting
fungicides (EBIFs). Biochem Pharmacol, 1994, 48: 1953-1965.
Zhukov, A, Werlinder, V, and Ingelman-Sundberg, M.: Purification and
characterization of two membrane bound serine proteinases from rat liver
microsomes active in degradation of cytochrome P450., Biochem Biophys Res
Commun, 1993, 197: 221-228.
Masimirembwa, C.M., Johansson, I., Hasler, J.A. and Ingelman-Sundberg, M.:
Genetic polymorphism of cytochrome P450 2D6 in Zimbabwean population.
Pharmacogenetics. 1993, 3: 275-280.
Rannug,, A., Alexandrie, A-K., Persson, I and Ingelman-Sundberg, M.: Genetic
polymorphism of cytochrome P450 1A1, 2D6 and 2E1. Regulation and toxicological
significance. J Occ Env. Med. 1995, 37: 25-36,.
Ronis, M.J.J., Hakkak, Ingelman-Sundberg, M and Badger, T.M.: Characterization of
cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol.
Biochem Pharmacol 1994, 48: 1823-1833,.
Morimoto, M., Hagbjörk, A.-L., Yvonne- Y-J., Fu, P.C. Albano, E. IngelmanSundberg, M. and French, S.W.: Modulation of experimental alcohol-induced liver
disease by cytochrome P450 2E1 inhibitors, Hepatology, 1995, 21:1610-1617.
Masimirembwa, C., Bertilsson, L., Johansson, J., Hasler J.A. and IngelmanSundberg, M: Phenotyping and genotyping of S-mephenytoin hydroxylase
(cytochrome P450 2C19) in a Shona population of Zimbabwe, Clin Pharmacol Ther,
1995, 57: 656-661.
Hu, Y., Ingelman-Sundberg, M. and Lindros, K.O.: Induction mechanisms of
cytochrome P450 2E1 in liver: Interplay between ethanol treatment and
starvation, Biochem Pharmacol, 1995, 50: 155-161.
Ronis, M.J.J., Huang, J., Longo, V., Tindberg, N. Ingelman-Sundberg, M. and
Badger, T.M.: Expression and distribution of cytochrome P450 enzymes in male rat
kidney: Effects of ethanol, acetone and dietary conditions, Biochem Pharmacol.,
1998, 55: 123-129.
Dahl, M.L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M and Sjöqvist, F.:
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the
molecular genetic basis. J Pharm Exp Ther, 1995, 274: 516-520.
Schmalix, W.A., Barrenscheen, M., Landsiedel, R., Janzowski, C., Eisenbrand, G.,
Gonzalez, F.J., Eliasson, E., Ingelman-Sundberg, M., Perchermeier, M., Greim, H.
and Doehmer, J.: Stable expression of human cytochrome P450 2E1 in V79 Chinese
Hamster Cells and metabolic activation of p-nitrophenol, chlorzoxazone and Nnitrosodimethylamine. Eur J Pharmacol, 1995, 293: 123-131.
Morimoto, M., Reitz, R.C., Morin, R.J., Nguyen, K., Ingelman-Sundberg, M. and
French, S.: CYP2E1 inhibitors partially ameliorate the changes in hepatic fatty acid
composition induced in rats by chronic administration of ethanol and a high fat
diet. J Nutrition, 1995, 125: 2953-2964.
4
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Birgander, R., Själander, A., Rannug, A., Alexandrie, A.-K., Ingelman-Sundberg, M.,
Seidegård, J., Tornling, G., Beckman, G. and Beckman, L.: p53 polymorphisms and
haplotypes in lung cancer. Carcinogenesis, 1995, 16: 2233-2236.
Hakkak, R., Korourian, S., Ronis, M.J.J., Ingelman-Sundberg, M., McGehee, R.E. and
Badger, T.M.: Effects of diet and ethanol on expression and localization of
cytochromes 2E1 and 2C7 in the colon of male rats. Biochem Pharmacol, 1996, 51:
61-69.
Hu, Y., Oscarson, M., Johansson, I., Yue, Q-Y, Dahl, M.L., Tabone, M., Arinco, S.,
Albano, E. and Ingelman-Sundberg, M.: Genetic polymorphism of the human
CYP2E1 - Characterization of two variant alleles. Mol Pharmacol, 1996, 51: 370376.
Lundqvist, E., Johansson, I., Dahl, M.-L. and Ingelman-Sundberg, M.: Genetic
mechanism for duplication and multiduplication of the human CYP2D6 gene and
methods for detection of duplicated CYP2D6 genes. Gene, 226:327-338, 1999.
McGehee, R.E., Ronis, M.J.J., Cowherd, R.M., Ingelman-Sundberg, M., and Badger,
T.M. Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4
cell model by ethanol. Biochem Pharmacol 1994, 48:1823-1833.
Ronis, M.J.J., Lindros, K.O. and Ingelman-Sundberg, M.: The cytochrome P4502E
subfamily in Cytochromes P450, Pharmacological and Toxicological Aspects
(Ioannides, I., Ed.) CRC Press, 1996, pp 211-239. (invited)
Ingelman-Sundberg, M., Ronis, M.J.J., Lindros, K.O., Eliasson, E. and Zhukov, A.:
Ethanol-inducible cytochrome P4502E1: Regulation, enzymology and molecular
biology, in Alcohol and Alcoholism, 1995, suppl 2, pp. 133-141.
Lindros, K.O., Badger, T.M., Ronis, M.J.J., Ingelman-Sundberg, M. and Koivusalo,
M.: Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase
inhibitor. J Pharm Exp Ther, 1995, 275: 79-83.
Gut, I., Nedelcheva, V., Soucek, P., Stopka, P., Gelboin, H.V. and IngelmanSundberg, M.: The role of CYP2E1 and 2B1 in metabolic activation of benzene
derivatives. Arch Toxicol, 1996, 71: 45-56.
Badger, T.M., Ronis, M.J.J., Ingelman-Sundberg, M. and Hakkak, R: Inhibition of
CYP2E1 activity does not abolish pulsatile urine alcohol concentrations during
alcohol infusions. Eur J Biochem, 1995, 230: 914-919.
Albano, E., Clot, P., Morimoto, M., Tomasi, A., Ingelman-Sundberg, M. and French,
S.: Role of cytochrome P4502E1-dependent formation of hydroxylethyl free radical
in the development of liver damage in rats intragastrically fed with ethanol.
Hepatology, 1995, 23: 155-163.
Tindberg, N., Baldwin, H.A., Cross, and Ingelman-Sundberg, M.: Induction of
cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory
factors and ischemic injury. Mol Pharmacol, 1996, 50: 1065-1072.
Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F and IngelmanSundberg, M.: Frequent distribution of ultrarapid metabolizers of debrisoquine in
an Ethiopian population carrying duplicated and multiduplicated functional
CYP2D6 alleles. J Pharm Exp Ther, 1996, 278: 441-446.
5
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
Backlund, M., Mkrtchian, S., Johansson, I. and Ingelman-Sundberg, M: Signal
transduction mediated activation of the aryl hydrocarbon receptor in rat
hepatoma H4IIE cells. J Biol Chem 1997, 272: 31755-31763.
Lindros, K.O., Oinonen, T., Johansson, I. and Ingelman-Sundberg. M.: Selective
centrilobular expression of the aryl hydrocarbon receptor in rat liver. J. Pharm Exp
Ther, 1997, 280: 506-511.
Stål, P., Johansson, I., Ingelman-Sundberg, M., Hagen, K. and Hultcrantz, R.:
Hepatotoxicity induced by iron overload and alcohol. Studies on the role of
chelatable iron, cytochrome P450 2E1 and lipid peroxidation. J Hepatol 1996, 25:
538-546.
Roh, H.-K., Dahl, M.-L., Johansson, I., Ingelman-Sundberg, M., Cha, Y.-N. and
Bertilsson, L.: Debrisoquine and S-mephenytoin hydroxylation phenotypes and
genotypes in a Korean population. Pharmacogenetics, 1996, 6: 441-447.
Clot, P., Albano, E., Eliasson, E., Tabone, M., Arico, S., Israel, Y., Moncada, C. and
Ingelman-Sundberg, M.: Cytochrome P4502E1 (CYP2E1) hydroxyethyl radical
adducts as the major antigenic determinants for autoantibody formation among
alcoholics, 1996, Gastroenterology, 111: 206-216.
Nedelcheva, V., Persson, I., Johansson, I. and Ingelman-Sundberg, M.: Genetic
polymorphism of human cytochrome P450 2E1. Meth Enzymol, 1996, 272: 218225.
Johansson, I., Lundqvist, E., Dahl, M.-L. and Ingelman-Sundberg, M: PCR-based
genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics, 1996, 6:
351-355.
Ingelman-Sundberg, M., Hagbjörk, A.-L., Ueng, Y.-F., Yamazaki, H. and Guengerich,
F.P.: High rates of substrate hydroxylation by human cytochrome P450 3A4 in
reconstituted membranous vesicles: Influence of membrane charge. Biochem
Biophys Res Commun, 1996, 221: 318-315.
French, S.W., Moromoto, M., Reitz, R.C., Koop, D., Klopfenstein, B, Estes, K. Clot,
P., Ingelman-Sundberg, M, and Albano, E.: Lipid peroxidation, CYP2E1 and
arachidonic acid metabolism in alcoholic liver disease in rats. J. Nutrition, 1997,
127(5): 907-911.
Daly, A.K., Brockmöller, J. Broly, F., Eichelbaum, M., Evans, W.E., Gonzalez, F.J.,
Huang, J-D., Idle, J.R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer,
U.A., Nebert, D.W., Steen, V.M., Wolf, C.R. and Zanger, U.M.: Nomenclature for
human CYP2D6 alleles, Pharmacogenetics, 1996, 6: 193-201.
Neve, E., Eliasson, E., Pronzato, M.A., Albano, E., Marinari, U and IngelmanSundberg, M.: Enzyme-specific transport of rat liver cytochrome P450 to the Golgi
apparatus, Arch Biochem Biophys, 1996, 333: 459-465.
Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L. and Ingelman-Sundberg, M: SMephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Pharmacogenetics, 1996, 6: 521-526.
Masimirembwa, C., Persson, I., Bertilsson, L., Hasler J. and Ingelman-Sundberg M.
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black
African population: association with diminished debrisoquine hydroxylase activity.
Br J Clin Pharmacol, 1996, 42: 713-719.
6
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
Song B.J., Koop, D.R., Ingelman-Sundberg, M., Nanji, A.A. and Cederbaum A.I.,
Ethanol-inducible cytochrome P450 (CYP2E1): Biochemistry, molecular biology and
clinical relevance: 1996 update. Alcohol Clin Exp Res, 1996, 20: 138A-146A.
Thurman, R.G., Ingelman-Sundberg, M., Cederbaum, A.I., Fernandez-Checa, J.C.,
Kato, S., Yokoyama, H. and Tsukamoto, H.: Oxidative stress in alcoholic liver injury.
Alcohol Clin Exp Res, 1996, 20: 162A-167A.
Tindberg, N. and Ingelman-Sundberg, M. Expression, catalytic activity, and
inducibility of cytochrome P450 2E1 (CYP2E1) in the rat central nervous system. J.
Neurochemistry, 1996, 67: 2066-2073.
Gouillon ZQ, Miyamoto K, Donohue TM, Wan YJ, French BA, Nagao Y, Fu P, Reitz
RC, Hagbjork A, Yap C, Yuan QX, Ingelman-Sundberg M, French SW. Role of CYP2E1
in the pathogenesis of alcoholic liver disease: modifications by cAMP and
ubiquitin-proteasome pathway. Front Biosci. 1999;4:A16-25.
Clot, P., Parola, M., Bellomo, G., Dianzani, U., Carini, R., Tabone, M., Aricò, S.,
Ingelman-Sundberg, M. and Albano, E.: Plasma membrane hydroxyethyl radical
adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to
alcohol. Gastroenterology, 1997, 113, 265-276.
Schrenk, D., Orzechowski, A., Schwarz, L.R., Snyder, R., Burchell, B., IngelmanSundberg, M. and Bock, K.W.: Phase II metabolism of benzene. Environ Health
Perspect, 1996, 104: 1183-1187.
Masimirembwa, C., Hasler, J., Bertilsson, L., Johansson, I., Ekberg, O. and
Ingelman-Sundberg, M.: Phenotype and genotype analysis of debrisoquine
hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity
and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin
Pharmacol, 1996, 51: 117-122.
McLellan, R.A., Oscarson, M., Seidegård, J., Evans, D.A.P. and Ingelman-Sundberg,
M: Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.
Pharmacogenetics, 1997, 7: 187-191.
Persson, I., Johansson, I. and Ingelman-Sundberg, M.: In vitro kinetics of two
human CYP1A1 variant enzymes suggested to be associated with interindividual
differences in cancer susceptibility. Biochem Biophys Res Commun, 1997, 231:
227-230.
Zhukov, A., Hellman, U. and Ingelman-Sundberg, M.: Purification and
characterization of hepsin from rat liver microsomes. Biochim Biophys Acta, 1997,
1337: 85-95.
Fang, C., Mkrtchian, S. and Ingelman-Sundberg, M.: Combination of direct DNA
sequencing with degenerate primer-mediated PCR and 5’-/3’-RACE to screen novel
cDNA sequences. Biotechniques, 1997, 23: 52-56.
Martini, R., Ingelman-Sundberg, M. And Murray M.: Pretranslational and
posttranslational regulation of rat hepatic CYPs 3A2 and 2E1 by disulfiram.
Biochem Pharmacol, 1997, 54: 1323-1329.
Weltman, M.D., Farrell, G.C., Hall, P., Ingelman-Sundberg, M. And Liddle, C.:
Hepatic CYP2E1 is increased in patients with non-alcoholic steatohepatitis.
Hepatology, 1998, 27: 128-133.
7
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
Lytton, S.D., Helander, A., Zhang-Gouillon, Z., Stokkeland, K., Bordone, R., Aricó, S.,
Albano, E., French, S.W. and Ingelman-Sundberg, M.: Autoantibodies against
cytochromes P450s 2E1 and 3A in alcoholics. Mol Pharmacol, 55:223-233, 1999.
Zhukov, A. and Ingelman-Sundberg, M.: Selective fast degradation of cytochrome
P450 2E1 in serum-deprived hepatoma cells by a mechanism sensitive to inhibitors
of vesicular transport. Eur J Biochem, 1997, 247: 37-43.
Mkrtchian, S., Fang, C., Hellman, U. and Ingelman-Sundberg, M.: A stress-inducible
endoplasmic reticulum protein, ERp29. Eur J Biochem, 1998, 251: 304-313.
Oscarson, M., Hidestrand, M., Johansson, I., and Ingelman-Sundberg, M.: A
combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in
enzyme function. Mol Pharmacol, 1997, 52: 1034-1040.
McLellan, R., Oscarson, M., Alexandrie, A.-K., Seidegård, J., Evans, D.A.P., Rannug,
A. and Ingelman-Sundberg, M.: Characterization of a human glutathione Stransferase mu cluster containing a duplicated GSTM1 gene causing ultrarapid
enzyme activity. Mol Pharmacol, 1997, 52:958-965.
Parola, M., Robino, G., Bordone, R., Leonarduzzi, G., Casini, A., Pinzani, M., Neve,
E., Bellomo, G., Dianzani MU., Ingelman-Sundberg M. and Albano, E.: Detection of
cytochrome P450A (CYP3A) in human hepatic stellate cells, Biochem Biophys Res
Commun, 1997, 238: 420-424.
Zhukov, A. and Ingelman-Sundberg, M: Relationship between cytochrome P450
catalytic cycling and stability: Fast degradation of ethanol-inducible cytochrome
P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron
donor NADPH-cytochrome P450 reductase, Biochem J., 1999, 340: 453-458
Albano, E., French, S. and Ingelman-Sundberg, M.: Cytochrome P4502E1 and
immune reactions associated to alcoholic liver disease. Alcoholism. Exp Clin Res,
1998, 22: 740-742.
Ingelman-Sundberg, M., Lytton, S. and Albano, E.: Role of cytochrome P450
enzymes in alcohol liver disease pathogenesis. Alcoholism. Exp Clin Res, 1998, 22:
739-740.
Fang, C., Lindros, KO., Badger, TM., Ronis, MJJ. and Ingelman-Sundberg, M.,
Zonated expression of cytokines in rat liver: Effect of chronic ethanol and the
cytochrome P4502E1 inhibitor chlormethiazole. Hepatology, 1998, 27: 1304-1310.
Bathum, L., Johansson, I., Ingelman-Sundberg, M., Hørder, M. and Brøsen, K:
Ultrarapid metabolism of sparteine: Frequency of alleles with duplicated CYP2D6
genes in a Danish population as determined by RFLP and long PCR. 1998,
Pharmacogenetics, 1998, 8: 119-123.
Korourian, S., Hakkak, R., Ronis, M.j.j., Shelnutt, S.R., Waldron, J., IngelmanSundberg, M. and Badger, T.M. Diet and risk of ethanol-induced hepatotoxicity:
Carbohydrate-fat relationships. Toxicol Sci. 47: 110-117, 1999.
French, S., Zhang-Gouillon, ZQ. and Ingelman-Sundberg, M.: The role of CYP2E1
induction by ethanol in the pathogenesis of alcoholic liver diseases as determined
by inhibitors of CYP2E1 transcription and post translation modulating factors.
1998, Alcoholism. Exp Clin Res, 1998, 22:738-739.
8
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
Ingelman-Sundberg, M.; The Gerhard Zbinden Memorial Lecture. Genetic
polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and
other xenobiotics. Arch Toxicol Suppl, 1997, 19:3-13.
Badger TM. Korourian S. Hakkak R. Ronis MJJ. Shelnutt SR. Ingelman-Sundberg M.
Waldron J.Carbohydrate deficiency as a possible factor in ethanol-induced hepatic
necrosis. Alc Clin Exp Res, 1998, 22: 742.
Nedelcheva V, Gut I, Soucek P, Tichavska B, Tynkova L, Mraz J, Guengerich FP,
Ingelman-Sundberg M Metabolism of benzene in human liver microsomes:
individual variations in relation to CYP2E1 expression Arch Toxicol 1999, 73:33-40
Ingelman-Sundberg, M. and Oscarson, M.: Prediction of human drug metabolism
using in vitro systems, Clin Pharmacology, 1998, 16: 7-15.
Ingelman-Sundberg, M.: Duplication, multiduplication and amplification of genes
encoding drug metabolising enzymes. Evolutionary, toxicological and clinical
pharmacological aspects, 1998, Drug Metab Rev, 31:449-459.
Nebert, D.W, Ingelman-Sundberg, M. and Daly, A:K: Genetic epidemiology of
environmental toxicity and cancer susceptibility: human allelic polymorphisms in
drugmetabolizing enzyme genes, their functional importance, and nomenclature
issues, 1999, Drug Met Rev 31: 467-487.
Backlund, M., Weidolf, L. and Ingelman-Sundberg, M.: Structural and mechanistic
aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole
derivatives in rat hepatoma H4IIE cells, 1999, Eur J Biochem 261:66-71.
Bernal, M.L., Sinues, B., Johansson, I., McLellan, R., Dahl, M-L., Ingelman-Sundberg,
M. and Bertilsson, L.: Ten percent of North Spanish subjects carry duplicated or
triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine,
1999, Pharmacogenetics, 9:657-60.
Wennerholm, A., Johansson, I., Massele, A.Y., Sayi, J., Alm, C., Aden Abdi, Y., Dahl,
M-L., Ingelman-Sundberg, M., Bertilsson, L. and Gustafsson, L.: Decreased capacity
for debrisoquine metabolism among black Tanzanians:analyses of the CYP2D6
genotype and phenotype.1999, Pharmacogenetics, 9:707-14
Mkrtchian, S., Baryshev, M., Matvijenko, O., Sharipo, A., Sandalova, T., Schneider,
G. and Ingelman-Sundberg, M.: Oligomerization properties of Erp29, an
endoplasmic reticulum stress protein, FEBS Letters, 1998, 431: 322-326.
Simi, A and Ingelman-Sundberg, M.: Posttranslational inhibition of cytochrome
P450 2E1 expression by chlormethiazole in Fao hepatoma cells. J Pharm Exp Ther,
1999, 289:847-852.
Ingelman-Sundberg M. Functional consequences of polymorphism of xenobiotic
metabolising enzymes, Toxicology Letters, 1998, 103: 155-160.
Yasar U. Eliasson E. Dahl ML. Johansson I. Ingelman-Sundberg M. Sjoqvist F.
Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a
Swedish population, Biochem Biophys Res Commun, 1999, 254: 628-631.
Oscarson M. Gullsten H. Rautio A. Bernal ML. Sinues B. Dahl ML. Stengard JH.
Pelkonen O. Raunio H.Ingelman-Sundberg M. Genotyping of human cytochrome
P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett, 1998, 438: 201-205.
9
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
Persson I, Johansson I, Lou YC, Yue QY, Duan LS, Bertilsson L, Ingelman-Sundberg
M Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung
cancer patients, Int J Cancer, 1999, 81: 325-329.
Jarvelainen HA, Fang C, Ingelman-Sundberg M, Lindros KO: Effect of chronic
coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines, Hepatology, 1999, 29:1503-1510.
Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML, Sinues B,
Hirvonen A, Raunio H, Pelkonen O, Ingelman-Sundberg M Characterisation and
PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a
Chinese population, FEBS Lett, 1999, 448:105-110.
Raucy JL, Ingelman-Sundberg M, Carpenter S, Rannug A, Rane A, Franklin M,
Romkes M Drug metabolizing enzymes in lymphocytes, J Biochem Mol Toxicol
1999, 13: 223-226.
Westlind A, Lofberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M:
Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to
Genetic Polymorphism in the 5'-Upstream Regulatory Region. Biochem Biophys
Res Commun, 1999, 259: 201-205.
Albano E, French S W, Ingelman-Sundberg M: Hydroxyethyl radicals in ethanol
hepatotoxicity, Front Biosci, 1999, 4:533-540.
Ingelman-Sundberg M, Oscarson M, McLellan R A: Polymorphic human
cytochrome P450 enzymes: an opportunity for invidualised drug treatment,
Trends Pharmacol Sci, 1999, 20: 342-349.
Ingelman-Sundberg M: Ethanol- inducible cytochrome P4502E1, Roles in Alcohol
Toxicity, Arqui Med, 1998, 12: 106-108.
Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M: Structional and functional
characterization of the 5´-flanking region of the rat and human cytochrome P450
2E1 genes. Identification of a polymorphic repeat in the human gene. Biochem.
Biophys. Res. Commun., 1999, 263: 286-293.
Chen GF, Ronis MJ, Ingelman-Sundberg M, Badger TM: Hormonal regulation of
microsomal cytochrome P4502E1 and P450 reductase in rat liver and kidney.
Xenobiotica, 1999, 29: 437-451.
Gouillon ZQ, Miyamoto K, Donohue T, Wan YJ, French B, Nagao Y, Fu P, Reitz R,
Hagbjörk A, Yap C, Yuan Q, Ingelman-Sundberg M, French S: Role of CYP2E1 in the
pathogenesis of alcoholic liver disease: modifications by cAMP and ubiquitinproteasome pathway. Front Biosci 1999, 4: A16-25.
Oscarson M, McLellan RA, Gullstén H, Agúndez JAG, Benítez J, Rautio A, Raunio H,
Pelkonen O, Ingelman-Sundberg M: Identification and characterisation of novel
polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS
Lett, 1999, 460: 321-327.
Neve EPA, Ingelman-Sundberg M: A soluble NH2-terminally truncated catalytically
active form of rat cytochrome P450 2E1 targeted to liver mitochondria. FEBS Lett,
1999, 460: 309-314.
Järveläinen HA, Fang C, Ingelman-Sundberg M, Lukkari T, Sippel H, Lindros KO:
Kupffer cell inactivation alleviates rat liver ethanol-induced steatosis and CYP2E1
10
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
induction but not inflammatory responses in rat liver, J Hepatol, 2000, 32: 900910.
Simi A, Ingelman-Sundberg M, Tindberg N: Neuroprotective agent chlormethiazole
attenuates c-fos, c-jun and AP-1 activation through inhibition of p38 MAP kinase, J
Cereb Blood F Met, 2000, 20:1077-1088.
Longo V, Ingelman-Sundberg M, Amato G, Salvetti A, Gervasi PG: Effect of
starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa.
Biochem Pharmacol 2000, 59:1425-1432.
Gouillon Z-Q, Lucas D, Li J, Hagbjork AL, French BA, Fu P, Ingelman-Sundberg M,
Donohue JrTM, French SW: Inhibition of ethanol-induced liver disease in the
intragastric feeding rat model by chlomethiazole, Proc Exp Soc Med, 2000, 224:
302-308.
Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW: Human cytochrome
P450 (CYP) genes: recommendations for the nomenclature of alleles.
Pharmacogenetics, 2000, 10: 91-93.
Neve EPA, Ingelman-Sundberg M: Molecular basis for the transport of
cytochrome P450 2E1 to the plasma membrane. 2000, J. Biol. Chem, 275:1713017135.
McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, IngelmanSundberg M: Characterization and functional analysis of two common human
cytochrome P450 1B1 variants, Arch Biochem Biophys, 2000, 378:175-181.
Bylund J, Hidestrand M, Ingelman-Sundberg M, Oliw EH: CYP4F8 of human seminal
vesicles is a prominent 19-hydroxylase of prostaglandin endoperoxides, J Biol
Chem, 2000, 275: 1844-1849.
Badger TM, Hoog J-O, Svensson S, McGehee RE, Fang C, Ronis MJJ, IngelmanSundberg M: Cyclic expression of class I alcohol dehydrogenase in male rats
treated with ethanol. Biochem Bioph Res Commun, 2000, 274: 684-688.
Bardag-Gorce F, Yuan QX, Li J, French BA, Fang C, Ingelman-Sundberg M, French
SW. The effect of ethanol-induced cytochrome p4502E1 on the inhibition of
proteasome activity by alcohol. Biochem Biophys Res Commun. 2000, 279: 23-29.
Werlinder V, Backlund M, Zhukov A, Ingelman-Sundberg M: Transcriptional and
posttranslational regulation of CYP1A1 by primaquine. J Pharm Exp Ther, 2001,
297: 206-214.
Rylander, T., Neve, E.P.A., Ingelman-Sundberg M. and Oscarson, M.: Identification
and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1)
Biochem Biophys Res Commun, 2001, 281: 529-535.
Westlind, A., Malmebo, S., Johansson, I., Otter, C, Andersson , T.B., IngelmanSundberg, M. and Oscarson, M.: Cloning and tissue distribution of a novel human
cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res
Commun, 2001, 281:1349-55.
Ingelman-Sundberg, M.: Genetic susceptibility to adverse effects of drugs and
environmental toxicants. The role of the CYP family of enzymes. Mutation
research, 2001, 482: 11-19..
Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L.L. and
Ingelman-Sundberg, M.: Characterization of a new CYP2D6 allele (CYP2D6*29)
11
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
commonly present in a black Tanzanian population causing reduced catalytic
activity, Pharmacogenetics, 2001, 11: 417-427..
Andersson, T.B., Sjöberg, H., Hoffman, K.-J., Boobis, A.R., Watts, P., Edwards RJ,
Lake BG., Price R.J., Renwic, A.B., Gómez-Lechón, M.J., Castell, J.V., IngelmanSundberg, M., Hidestrand, M., Goldfarb, P., Lewis, D., Corcos, L., Guillouzo, A.,
Taavitsainen, P. and Pelkonen, O.: An assessment of human liver-derived in vitro
systems to predict the in vivo metabolism and clearance of Almokalant, Drug Met
Disp, 2001, 29:712-20.
Neve EP, Ingelman-Sundberg M.: Identification and characterization of a
mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). J Biol Chem.
2001, 276:11317-22.
Pitarque, M., von Richter, O., Oke, B., Berkkan, H, Oscarson, M and IngelmanSundberg M.: Identification of a Single Nucleotide Polymorphism in the TATA box
of the CYP2A6 Gene: Impairment of its Promoter Activity. Biochem Biophys Res
Commun, 2001, 284: 455-460.
Scordo, M.G., Aklillu, E., Yasar, U., Dahl, M.-L., Spina, E., and Ingelman-Sundberg,
M.: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a BlackAfrican population. Br J Clin Pharm, 2001, 52: 447-450.
Pelkonen, O., Myllynen, P., Taavitsainen, P., Boobis, A.R., Watts, P., Lake, B.G.,
Price, R.J., Renwick, A.B., Gómez-Lechón, M.-J., Castell, J.V., Ingelman-Sundberg,
M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D.F.V.:
Carbamazepine: a “blind” assessment of CYP-associated metabolism and
interactions in human liver-derived in vitro systems. 2001, Xenobiotica, 31:321343.
Yasar, Ü., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman-Sundberg, M., Dahl,
M.-L., Eliasson, E.: The role of CYP2C9 polymorphism in losartan oxidation. 2001,
Drug Met Disp, 29: 1051-1056.
Liepinsh, E., Baryshev, M., Sharipo, A., Ingelman-Sundberg, M., Otting, G.,
Mkrtchian, S.: Thioredoxin fold as a homodimerization module in the putative
chaperone ERp29: NMR structures of the domains and experimental model of the
54 kDa homodimer. Structure, 2001, 9: 457-471.
Hosseinpour F, Hidestrand M, Ingelman-Sundberg M, Wikvall K. The Importance of
Residues in Substrate Recognition Site 3 for the Catalytic Function of CYP2D25
(Vitamin D 25-Hydroxylase). Biochem Biophys Res Commun. 2001; 288:1059-63.
Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M,
Ingelman-Sundberg M. CYP2B6 and Cyp2c19 as the major enzymes responsible for
the metabolism of selegiline, a drug used in the treatment of parkinson's disease,
as revealed from experiments with recombinant enzymes. Drug Metab Dispos.
2001; 29:1480-4.
Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human
Cytochrome P-450 (CYP) Genes: A Web Page for the Nomenclature of Alleles.
Cancer Epidemiol Biomarkers Prev. 2001; 10:1307-8.
Garte S, …. Ingelman-Sundberg M, … Persson I, … Vineis P, Yu MC, Taioli E.
Metabolic gene polymorphism frequencies in control populations. Cancer
Epidemiol Biomarkers Prev. 2001; 10:1239-48.
12
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
Hedberg JJ, Backlund M, Stromberg P, Lonn S, Dahl ML, Ingelman- Sundberg M,
Hoog JO. Functional polymorphism in the alcohol dehydrogenase 3 (ADH3)
promoter. Pharmacogenetics. 2001; 11:815-24.
Evans WE, Ingelman-Sundberg M. Resequencing the sulfotransferase SULT1 gene
provides new insights, while illuminating challenges that lie ahead for
pharmacogenomics. Pharmacogenetics. 2001; 11:745-6.
Ingelman-Sundberg M, Evans WE. Unravelling the functional genomics of the
human CYP2D6 gene locus. Pharmacogenetics. 2001; 11:553-4.
Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more
efficient pharmacotherapy. J Intern Med. 2001; 250:186-200..
Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D,
Brockmoller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A,
Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M,
Kremers P, LeMarchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A,
Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stucker I, To-Figueras J,
Brennan P, Taioli E. Meta- and pooled analyses of the effects of glutathione Stransferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis.
2002; 23:1343-50.
Bardag-Gorce F, French BA, Li J, Riley NE, Yuan QX, Valinluck V, Fu P, IngelmanSundberg M, Yoon S, French SW. The importance of cycling of blood alcohol levels
in the pathogenesis of experimental alcoholic liver disease in rats.
Gastroenterology. 2002; 123:325-35.
Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity.
Toxicology. 2002;181-182:447-52..
Gavrilovich Zgoda V, Arison B, Mkrtchian S, Ingelman-Sundberg M, Almira Correia
M. Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a
role for glutathione and GRP94 in the heme-protein assembly. Arch Biochem
Biophys. 2002; 408:58-68.
Ingelman-Sundberg M, Oscarson M. Human CYP allele database: submission
criteria procedures and objectives. Methods Enzymol. 2002; 357:28-36.
Simi A, Porsmyr-Palmertz M, Hjerten A, Ingelman-Sundberg M, Tindberg N. The
neuroprotective agents chlomethiazole and SB203580 inhibit IL-1beta signalling
but not its biosynthesis in rat cortical glial cells. J Neurochem. 2002; 83:727-37.
Oscarson M, McLellan RA, Asp V, Ledesma M, Ruiz ML, Sinues B, Rautio A,
Ingelman-Sundberg M. Characterization of a novel CYP2A7/CYP2A6 hybrid allele
(CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat. 2002; 20:275-83.
Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for
environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as
demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in
Sweden. Pharmacogenetics. 2002; 12:375-83.
Oscarson M, Ingelman-Sundberg M. CYPalleles: A Web Page for Nomenclature of
Human Cytochrome P450 Alleles. Drug Metab Pharmacokinet. 2002; 17:491-5.
Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J,
Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E. Microsomal epoxide hydrolase
13
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
polymorphisms and lung cancer risk: a quantitative review. Biomarkers. 2002;
7:230-41..
Bardag-Gorce F, French BA, Li J, Riley NE, Yuan QX, Valinluck V, Fu P, IngelmanSundberg M, Yoon S, French SW. The importance of cycling of blood alcohol levels
in the pathogenesis of experimental alcoholic liver disease in rats.
Gastroenterology. 2002; 123:325-35.
Lytton SD, Berg U, Nemeth A, Ingelman-Sundberg M. Autoantibodies against
cytochrome P450s in sera of children treated with immunosuppressive drugs. Clin
Exp Immunol. 2002; 127:293-302.
Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M.
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in
an Ethiopian population. Mol Pharmacol. 2002; 61:586-94.
Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M,
Bertilsson L, Hasler J, Gustafsson LL. The African-specific CYP2D617 allele encodes
an enzyme with changed substrate specificity. Clin Pharmacol Ther. 2002; 71:7788.
Neve EP, Hidestrand M, Ingelman-Sundberg M. Identification of sequences
responsible for intracellular targeting and membrane binding of rat CYP2E1 in
yeast. Biochemistry. 2003; 42:14566-75.
Tamasi V, Hazai E, Porsmyr-Palmertz M, Ingelman-Sundberg M, Vereczkey L,
Monostory K. GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4yl)propionic acid] antagonist, is a CYP2E1 inducer. Drug Metab Dispos.
2003;31(11):1310-4.
Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. Xanthine
oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin
Pharmacol. 2003; 59:533-6.
Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, IngelmanSundberg M. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction
and expression: characterization of novel haplotypes with single-nucleotide
polymorphisms in intron 1. Mol Pharmacol. 2003; 64:659-69.
Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick
AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo
A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O. Comparative
studies on the cytochrome p450-associated metabolism and interaction potential
of selegiline between human liver-derived in vitro systems. Drug Metab Dispos.
2003; 31:1093-102.
Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S,
Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stucker I,
Sugimura H, Taioli E. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung
cancer (United States). Cancer Causes Control. 2003; 14:339-46.
Rylander-Rudqvist T, Wedren S, Granath F, Humphreys K, Ahlberg S, Weiderpass E,
Oscarson M, Ingelman-Sundberg M, Persson I. Cytochrome P450 1B1 gene
polymorphisms and postmenopausal breast cancer risk. Carcinogenesis. 2003;
24:1533-9.
14
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson
I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. Comparative analysis of CYP3A
expression in human liver suggests only a minor role for CYP3A5 in drug
metabolism. Drug Metab Dispos. 2003; 31:755-61.
Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-Sundberg M, Persson I,
Magnusson C. Catechol-O-methyltransferase gene polymorphism and postmenopausal breast cancer risk. Carcinogenesis. 2003; 24:681-7.
Rodriguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M, GomezLechon MJ, Castell JV. Transcriptional regulation of human CYP3A4 basal
expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear
factor-3 gamma. Mol Pharmacol. 2003; 63:1180-9.
Aklillu E, Hidestrand M, Ingelman-Sundberg M, Malmebo S, Westlind A. Recent
Progress in Drug Metabolism Research. Drug News Perspect. 2002; 15:528-534.
Badger TM, Ronis MJ, Seitz HK, Albano E, Ingelman-Sundberg M, Lieber CS. Alcohol
metabolism: role in toxicity and carcinogenesis. Alcohol Clin Exp Res. 2003;
27:336-47.
Hakkola J, Hu Y, Ingelman-Sundberg M. Mechanisms of down-regulation of CYP2E1
expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther.
2003; 304:1048-54.
Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V,
Haugen A, Hirvonen A, Ingelman-Sundberg M, Kihara M, Kiyohara C, Kremers P, Le
Marchand L, Ohshima S, Pastorelli R, Rannug A, Romkes M, Schoket B, Shields P,
Strange RC, Stucker I, Sugimura H, Garte S, Gaspari L, Taioli E. CYP1A1 T3801 C
polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls.
Int J Cancer. 2003; 104:650-7.
Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications
in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004; 25:193200.
Ronis MJ, Hakkak R, Korourian S, Albano E, Yoon S, Ingelman-Sundberg M, Lindros
KO, Badger TM. Alcoholic liver disease in rats fed ethanol as part of oral or
intragastric low-carbohydrate liquid diets. Exp Biol Med. 2004; 229:351-60.
Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M.
Hepatic expression of multiple acute phase proteins and down-regulation of
nuclear receptors after acute endotoxin exposure. Biochem Pharmacol. 2004;
67:1389-97.
Butura A, Johansson I, Nilsson K, Warngard L, Ingelman-Sundberg M, SchuppeKoistinen I. Differentiation of human hepatoma cells during confluence as
revealed by gene expression profiling. Biochem Pharmacol. 2004; 67:1249-58.
Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M.
Characterization and tissue distribution of a novel human cytochrome P450CYP2U1. Biochem Biophys Res Commun. 2004; 315:679-85.
Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, IngelmanSundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for
promoter activity. Hum Mutat. 2004; 23:258-66.
15
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
Backlund M, Ingelman-Sundberg M. Different structural requirements of the
ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity
ligand binding and receptor activation. Mol Pharmacol. 2004; 65:416-25.
Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes:
properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. 2004;
369:89-104.
Gomez A, Ingelman-Sundberg M, Johansson I, Karlgren M, Rodriguez-Antona C,
Sim SC. New approaches and applications in chemical biology. Drug News
Perspect. 2004 17:594-605.
Vidali M, Hidestrand M, Eliasson E, Mottaran E, Reale E, Rolla R, Occhino G, Albano
E, Ingelman-Sundberg M. Use of molecular simulation for mapping
conformational CYP2E1 epitopes. J Biol Chem. 2004; 279:50949-55.
Rylander-Rudqvist T, Wedren S, Jonasdottir G, Ahlberg S, Weiderpass E, Persson I,
Ingelman-Sundberg M. Cytochrome P450 1B1 gene polymorphisms and
postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev.
2004; 13:1515-20.
von Richter O, Pitarque M, Rodriguez-Antona C, Testa A, Mantovani R, Oscarson
M, Ingelman-Sundberg M. Polymorphic NF-Y dependent regulation of human
nicotine C-oxidase (CYP2A6). Pharmacogenetics. 2004; 14:369-79.
Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty
acids for the prevention of cancer: a review of potential mechanisms. Am J Clin
Nutr. 2004; 79:935-45..
Ronis MJ, Korourian S, Yoon S, Ingelman-Sundberg M, Albano E, Lindros KO,
Badger TM. Lack of sexual dimorphism in alcohol-induced liver damage (ALD) in
rats treated chronically with ethanol-containing low carbohydrate diets: The role
of ethanol metabolism and endotoxin. Life Sci. 2004; 75:469-83.
Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C,
Autrup H, Autrup JL, Baranova H, Bathum L, Boffetta P, Bouchardy C, Brockmoller
J, Butkiewicz D, Cascorbi I, Clapper ML, Coutelle C, Daly AK, Muzi G, Dolzan V,
Duzhak TG, Farker K, Golka K, Haugen A, Hein DW, Hildesheim A, Hirvonen A,
Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Katoh T, Kihara M, Ono-Kihara
M, Kim H, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, London S,
Manni JJ, Maugard CM, Morgan GJ, Morita S, Nazar-Stewart V, Kristensen VN, Oda
Y, Parl FF, Peters WH, Rannug A, Rebbeck T, Pinto LF, Risch A, Romkes M, Salagovic
J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnett D, Strange RC, Stucker I,
Sugimura H, To-Figueras J, Vineis P, Yu MC, Zheng W, Pedotti P, Taioli E.
Association of metabolic gene polymorphisms with tobacco consumption in
healthy controls. Int J Cancer. 2004; 110:266-70.
Pitarque M, Rodriguez-Antona C, Oscarson M, Ingelman-Sundberg M.
Transcriptional regulation of the human cytochrome P450 2A6 (CYP2A6) gene. J
Pharmacol Exp Ther. 2005; 313:814-22
Andersson S, Hofmann Y, Nordling A, Li XQ, Nivelius S, Andersson TB, IngelmanSundberg M, Johansson I. Characterization and partial purification of the rat and
human enzyme systems active in the reduction of N-hydroxymelagatran and
benzamidoxime. Drug Metab Dispos. 2005, 33:570-8.
16
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
217.
218.
219.
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6
(CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Pharmacogenomics J. 2005; 5:6-13.
Backlund M, Ingelman-Sundberg M. Regulation of aryl hydrocarbon receptor
signal transduction by protein tyrosine kinases. Cell Signal. 2005; 17:39-48.
Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drugmetabolizing enzymes: implications for a safer and more effective drug therapy.
Philos Trans R Soc Lond B Biol Sci. 2005; 360:1563-70.
Ronis MJ, Butura A, Sampey BP, Shankar K, Prior RL, Korourian S, Albano E,
Ingelman-Sundberg M, Petersen DR, Badger TM. Effects of N-acetylcysteine on
ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic
Biol Med. 2005; 39:619-630.
Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression
is high in a fraction of adult human livers and partially associated with the
CYP3A7*1C allele. Pharmacogenet Genomics. 2005; 15:625-31.
Raimondi S, Boffetta P, Anttila S, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper
ML, Dragani TA, Garte S, Gsur A, Haidinger G, Hirvonen A, Ingelman-Sundberg M,
Kalina I, Lan Q, Leoni VP, Marchand LL, London SJ, Neri M, Povey AC, Rannug A,
Reszka E, Ryberg D, Risch A, Romkes M, Ruano-Ravina A, Schoket B, Spinola M,
Sugimura H, Wu X, Taioli E. Metabolic gene polymorphisms and lung cancer risk in
non-smokers An update of the GSEC study. Mutat Res. 2005, 592:45-57
Ingelman-Sundberg M. The human genome project and novel aspects of
cytochrome P450 research.Toxicol Appl Pharmacol. 2005 207:52-6
Karlgren M, Miura SI, Ingelman-Sundberg M. Novel extrahepatic cytochrome
P450s. Toxicol Appl Pharmacol. 2005; 207:57-61
Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. Characterization of
common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res. 2005; 65:510511.
Rodriguez-Antona C, Axelson M, Otter C, Rane A, Ingelman-Sundberg M. A novel
polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene
CYP3AP1. J Biol Chem. 2005 ; 280:28324-31.
Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Identification and
phenotype characterization of two CYP3A haplotypes causing different enzymatic
capacity in fetal livers. Clin Pharmacol Ther. 2005; 77:259-70.
Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M,
Hartung T, Coecke S. Substrate specific metabolism by polymorphic cytochrome
P450 2D6 alleles. Toxicol In Vitro. 2005; 19:621-9.
Simi A, Edling Y, Ingelman-Sundberg M, Tindberg N. Activation of c-fos by
lipopolysaccharide in glial cells via p38 mitogen-activated protein kinasedependent activation of serum or cyclic AMP/calcium response element. J
Neurochem. 2005; 92:915-24.
Ingelman-Sundberg M, Sim SC, Nebert DW. Coffee, myocardial infarction, and CYP
nomenclature. JAMA. 2006; 296:764-5;
Sim SC, Ingelman-Sundberg M. The human cytochrome P450 Allele Nomenclature
Committee Web site: submission criteria, procedures, and objectives. Methods
Mol Biol. 2006; 320:183-91.
Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, IngelmanSundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, Vinks
AA, Nassr N, von Richter O, Jin L, Nebert DW. Search for an association between
the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet
Genomics. 2006, 16:359-67.
17
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.
231.
232.
Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech
K, Ingelman-Sundberg M, von Richter O. Identification and characterization of
CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol
Ther. 2006; 79:339-49.
Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics
and cancer. Oncogene. 2006; 25:1679-91.
Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R,
Crespi CL, Cunningham ML, Elaut G, Eletti B, Freidig A, Gennari A, Ghersi-Egea JF,
Guillouzo A, Hartung T, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W,
Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke
F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai
E, Vericat JA, Worth A. Metabolism: a bottleneck in in vitro toxicological test
development. The report and recommendations of ECVAM workshop 54. Altern
Lab Anim. 2006; 34:49-84.
Wang J, Sönnerborg A, Rane A, Josephson F, Lundgren S, Ståhle L, IngelmanSundberg M. Identification of a novel specific CYP2B6 allele in Africans causing
impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;
16:191-8.
Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, Bernal ML,
Ramón y Cajal S, Johansson I, Ingelman-Sundberg M. Tumor-specific expression of
the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun.
2006; 341:451-8.
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, IngelmanSundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug
metabolism relevant for the drug response to proton pump inhibitors and
antidepressants. Clin Pharmacol Ther. 2006; 79:103-13.
Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and
individualized drug therapy. Annu Rev Med. 2006; 57:119-37.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of
cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic,
pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116:496-526.
Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M.
Expression of CYP2W1 in colon tumors: regulation by gene methylation.
Pharmacogenomics. 2007; 8:1315-1325.
Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M,
Ingelman-Sundberg M. Characterization of novel CYP2C8 haplotypes and their
contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2007
8:268-77.
Söderdahl T, Küppers-Munther B, Edsbagge J, Andersson TB, Björquist P,
Cotgreave I, Jernström B, Ingelman-Sundberg M, Johansson I. Expression of drug
metabolizing enzymes in hepatocyte-like cells derived from human embryonic
stem cells. Biochem Pharmacol. 2007; 74:496-503.
Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L.
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the
genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol.
2007; 63:537-46.
Arakelyan KP, Sahakyan YA, Hayrapetyan LR, Khudaverdyan DN, IngelmanSundberg M, Mkrtchian S, Ter-Markosyan AS. Calcium-regulating peptide
hormones and blood electrolytic balance in chronic heart failure. Regul Pept.
2007; 142:95-100. Epub 2007 Feb 16.
18
233.
234.
235.
236.
237.
238.
239.
240.
241.
242.
243.
244.
245.
246.
247.
Herman D, Dolzan V, Ingelman-Sundberg M. Characterization of the novel
defective CYP2C9*24 allele. Drug Metab Dispos. 2007; 35:831-4.
Afzelius L, Ingelman-Sundberg M, Karlgren M, Rodriguez-Antona C. Novel aspects
of drug metabolism and transport. Drug News Perspect. 2006; 19:637-51.
Karlgren M, Ingelman-Sundberg M. Tumour-specific expression of CYP2W1: its
potential as a drug target in cancer therapy. Expert Opin Ther Targets. 2007;
11:61-7.
Edling Y, Ingelman-Sundberg M, Simi A. Glutamate activates c-fos in glial cells via a
novel mechanism involving the glutamate receptor subtype mGlu5 and the
transcriptional repressor DREAM. Glia. 2007; 55:328-40.
Ek M, Söderdahl T, Küppers-Munther B, Edsbagge J, Andersson TB, Björquist P,
Cotgreave I, Jernström B, Ingelman-Sundberg M, Johansson I. Expression of drug
metabolizing enzymes in hepatocyte-like cells derived from human embryonic
stem cells. Biochem Pharmacol. 2007; 74:496-503.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of
cytochrome P450 polymorphisms on drug therapies: pharmacogenetic,
pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116:496-526.
Epub 2007 Oct 9
Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M.
Expression of CYP2W1 in colon tumors: regulation by gene methylation.
Pharmacogenomics. 2007; 8:1315-25.
Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M,
Ingelman-Sundberg M. Characterization of novel CYP2C8 haplotypes and their
contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2008;
8:268-77. Epub 2007 Oct 9.
Ek M, Söderdahl T, Küppers-Munther B, Edsbagge J, Andersson TB, Björquist P,
Cotgreave I, Jernström B, Ingelman-Sundberg M, Johansson I. Expression of drug
metabolizing enzymes in hepatocyte-like cells derived from human embryonic
stem cells. Biochem Pharmacol. 2007; 74:496-503. Epub 2007 May 17.
Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L.
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the
genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol.
2007; 63:537-46. Epub 2007 Mar 17.
Herman D, Dolzan V, Ingelman-Sundberg M. Characterization of the novel
defective CYP2C9*24 allele. Drug Metab Dispos. 2007;35:831-4. Epub 2007 Mar 1.
Johansson I, Ingelman-Sundberg M. Current research in drug metabolism, drug
transport and drug development. Drug News Perspect. 2008;21:518-28.
Butura A, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, SchuppeKoistinen I, Ingelman-Sundberg M. The impact of CYP2E1 on the development of
alcoholic liver disease as studied in a transgenic mouse model. J Hepatol.
2009;50:572-83. Epub 2008 Dec 25.
Edler D, Stenstedt K, Ohrling K, Hallström M, Karlgren M, Ingelman-Sundberg M,
Ragnhammar P. The expression of the novel CYP2W1 enzyme is an independent
prognostic factor in colorectal cancer - a pilot study. Eur J Cancer. 2009;45:705-12.
Epub 2008 Dec 30.
Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC,
Bertilsson L, Ingelman-Sundberg M, Eliasson E. Kinetics of omeprazole and
escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin
Pharmacol. 2008; 64:1175-9. Epub 2008 Jul 25.
19
248.
249.
250.
251.
252.
253.
254.
255.
256.
257.
258.
259.
260.
261.
Edling Y, Sivertsson L, Andersson TB, Porsmyr-Palmertz M, Ingelman-Sundberg M.
Pro-inflammatory response and adverse drug reactions: mechanisms of action of
ximelagatran on chemokine and cytokine activation in a monocyte in vitro model.
Toxicol In Vitro. 2008; 22:1588-94. Epub 2008 Jul 2.
Neve EP, Ingelman-Sundberg M. Intracellular transport and localization of
microsomal cytochrome P450. Anal Bioanal Chem. 2008;392:1075-84. Epub 2008
Jun 8.
Chavarria-Soley G, Sticht H, Aklillu E, Ingelman-Sundberg M, Pasutto F, Reis A,
Rautenstrauss B. Mutations in CYP1B1 cause primary congenital glaucoma by
reduction of either activity or abundance of the enzyme. Hum Mutat.
2008;29:1147-53.
Lee KM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, Kiyohara C,
Min S, Lan Q, Le Marchand L, Lin P, Lung ML, Pinarbasi H, Pisani P, Srivatanakul P,
Seow A, Sugimura H, Tokudome S, Yokota J, Taioli E. CYP1A1, GSTM1, and GSTT1
polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian
populations. Cancer Epidemiol Biomarkers Prev. 2008;17:1120-6. Epub 2008 May
7.
Ronis MJ, Butura A, Korourian S, Shankar K, Simpson P, Badeaux J, Albano E,
Ingelman-Sundberg M, Badger TM. Cytokine and chemokine expression associated
with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total
enteral nutrition. Exp Biol Med (Maywood). 2008;233:344-55.
Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E,
Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17
allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol.
2008;65:767-74. Epub 2008 Feb 20.
Löfgren S, Baldwin RM, Hiratsuka M, Lindqvist A, Carlberg A, Sim SC, Schülke M,
Snait M, Edenro A, Fransson-Steen R, Terelius Y, Ingelman-Sundberg M.
Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization
of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos. 2008;
36:955-62. Epub 2008 Feb 14.
Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe
adverse drug reactions. N Engl J Med. 2008;358:637-9.
Johansson I, Ingelman-Sundberg M. CNVs of human genes and their implication in
pharmacogenetics. Cytogenet Genome Res. 2008;123:195-204. Epub 2009 Mar 11.
Mwinyi J, Nekvindová J, Cavaco I, Hofmann Y, Pedersen RS, Landman E, Mkrtchian
S, Ingelman-Sundberg M. New Insights into the Regulation of CYP2C9 Gene
Expression: The Role of the Transcription Factor GATA-4. Drug Metab Dispos.
2010; 38:415-21. Epub 2009 Dec 7.
Edling Y, Sivertsson LK, Butura A, Ingelman-Sundberg M, Ek M. Increased
sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture
model. Toxicol In Vitro. 2009; 23:1387-95. Epub 2009 Jul 23.
Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of
cytochrome P450 expression: a gap between DNA and protein.
Pharmacogenomics. 2009; 10:1067-76.
Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, Wolf CR, Flück CE, Pandey
AV, Henderson CJ, Porter TD, Daly AK, Nebert DW, Ingelman-Sundberg M.
Nomenclature for alleles of the cytochrome P450 oxidoreductase gene.
Pharmacogenet Genomics. 2009; 19:565-6.
Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottée L, Bièche I,
Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Declèves X, Duyckaerts
C, Loriot MA. Xenobiotic-metabolizing enzymes and transporters in the normal
20
262.
263.
264.
265.
266.
267.
268.
269.
270.
271.
272.
273.
274.
275.
human brain: regional and cellular mapping as a basis for putative roles in cerebral
function. Drug Metab Dispos. 2009;37:1528-38.
Huynh L, Masereeuw R, Friedberg T, Ingelman-Sundberg M, Manivet P. In silico
platform for xenobiotics ADME-T pharmacological properties modeling and
prediction. Part I: Beyond the reduction of animal model use. Drug Discov Today.
2009; 14:401-5.
Löfgren S, Baldwin RM, Carlerös M, Terelius Y, Fransson-Steen R, Mwinyi J,
Waxman DJ, Ingelman-Sundberg M. Regulation of human CYP2C18 and CYP2C19 in
transgenic mice: influence of castration, testosterone, and growth hormone. Drug
Metab Dispos. 2009;37:1505-12.
Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen AC, Bertilsson L, IngelmanSundberg M, Aklillu E. Allele-specific expression and gene methylation in the
control of CYP1A2 mRNA level in human livers. Pharmacogenomics J. 2009;9:20817.
Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual
differences in drug response. Clin Pharmacol Ther. 2009;85:426-30.
Sutti, S, Vidali, M., Mombello, C, Sartori, M., Ingelman-Sundberg M and Albano.
E. Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic
hepatitis C: possible role for molecular mimicry. J. Hepatol. 2010, 53:431-438
Ingelman-Sundberg M and Sim SC. Pharmacogenetic biomarkers as tools for
improved drug therapy; emphasis on the cytochrome P450 system. Biochem
Biophys Res Commun. 2010, 396:90-94 (KI 200 anniversary)
Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS,
Weihe P, Edvardsen H, Kristensen VN, Brøsen K, Ingelman-Sundberg M. Linkage
disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9
alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin
Pharmacol. 2010 ;66:1199-205
Kotsovolou O, Ingelman-Sundberg M, Lang MA, Marselos M, Overstreet DH,
Papadopoulou-Daifoti Z, Johanson I, Fotopoulos A, Konstandi M. Hepatic drug
metabolizing profile of Flinders Sensitive Line rat model of depression. Prog
Neuropsychopharmacol Biol Psychiatry. 2010; 34:1075-84. Epub 2010 Jun 4.
Pasutto F, Chavarria-Soley G, Mardin CY, Michels-Rautenstrauss K, IngelmanSundberg M, Fernández-Martínez L, Weber BH, Rautenstrauss B, Reis A.
Heterozygous loss-of-function variants in CYP1B1 predispose to primary openangle glaucoma. Invest Ophthalmol Vis Sci. 2010; 51:249-54. Epub 2009 Jul 30.
Sim SC, Nordin L, Andersson TM, Virding S , Olsson M, Pedersen NL, and
Ingelman-Sundberg M: Association between CYP2C19 polymorphism and
depressive symptoms. Am J Med Genet B Neuropsychiatr Genet. 2010 153B:11606.
Andersson, TB, and Ingelman-Sundberg M., Livers cells derived from Human
embryonic stem cells. Progress and potential use in ADMET applications. Drug Disc
Today: Technologies 2010; 4, in press
Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L.
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype,
sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol. 2010 ;66:871-7
Sim SC, and Ingelman-Sundberg M, The Human Cytochrome P450 (CYP) Allele
Nomenclature Website – a peer-reviewed database of CYP variants and their
associated effects. Human Genomics 2010; 4:278-81.
Sivertsson L, Ek M, Darnell M, Edebert I, Ingelman-Sundberg M, Neve EP. CYP3A4
catalytic activity is induced in confluent Huh7 hepatoma cells. Drug Metab Dispos.
2010;38:995-1002.
21
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
288.
289.
290.
291.
Mwinyi, J., Hofmann Y, Steen Pedersen R., Nekvindova J., Cavaco I. Mkrtchian S.
and Ingelman-Sundberg M: The transcription factor GATA-4 regulates cytochrome
P4502C19 gene expression. Life Sci. 2010, 86:699-706
Neve EP, Ingelman-Sundberg M. .Cytochrome P450 proteins: retention and
distribution from the endoplasmic reticulum. Curr Opin Drug Discov Devel. 2010;
13:78-85.
Brolén G, Sivertsson L, Björquist P, Eriksson G, Ek M, Semb H, Johansson I,
Andersson TB, Ingelman-Sundberg M, Heins N. Hepatocyte-like cells derived from
human embryonic stem cells specifically via definitive endoderm and a progenitor
stage. J Biotechnol. 2010; 145:284-94. Epub 2009 Nov 20.
Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M.
Molecular genetics and epigenetics of the cytochrome P450 gene family and its
relevance for cancer risk and treatment. Hum Genet. 2010; 127:1-17
Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, Edler D, Mkrtchian S,
Ingelman-Sundberg M. Colorectal cancer specific cytochrome P450 2W1
(CYP2W1): intracellular localization, glycosylation, and catalytic activity. Mol
Pharmacol. 2010 Mol Pharmacol. 2010 ;78:1004-11.
Mwinyi, J, Cavaco, I, Steen Pedersen, R. Persson, A., Burkhardt, S., Mkrtchian S.
and Ingelman-Sundberg M. Regulation of CYP2C19 expression by estrogen
receptor alpha. Implications for estrogen dependent inhibition of drug
metabolism. Mol Pharmacol 2010,;78:886-94
Wang J, Hu Y, Nekvindova J, Ingelman-Sundberg M, Neve EP. IL-4-mediated
transcriptional regulation of human CYP2E1 by two independent signaling
pathways. Biochem Pharmacol. 2010; 80:1592-600. Epub 2010 Aug 17.
Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. Hum
Genomics. 2010; 4:402-5.
Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of
pharmacogenetics. Hum Mutat. 2011 ;32:526-31.
Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in
current and future drug therapy. Trends Pharmacol Sci. 2011;32:72-81
Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology--with
emphasis on cytochrome P450. Toxicol Sci. 2011 ;120:1-13.
Yildirimman R, Brolén G, Vilardell M, Eriksson G, Synnergren J, Gmuender H,
Kamburov A, Ingelman-Sundberg M, Castell J, Lahoz A, Kleinjans J, van Delft J,
Björquist P, Herwig R. Human embryonic stem cell derived hepatocyte-like cells as
a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011
124:278-90
Mandenius CF, Andersson TB, Alves PM, Batzl-Hartmann C, Björquist P, Carrondo
MJ, Chesne C, Coecke S, Edsbagge J, Fredriksson JM, Gerlach JC, Heinzle E,
Ingelman-Sundberg M, Johansson I, Küppers-Munther B, Müller-Vieira U, Noor F,
Zeilinger K. Toward preclinical predictive drug testing for metabolism and
hepatotoxicity by using in vitro models derived from human embryonic stem cells
and human cell lines - a report on the Vitrocellomics EU-project. Altern Lab Anim.
2011;39:147-71.
Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its
relevance to adverse drug reactions. Clin Pharmacol Ther. 2011;89:902-7.
Mwinyi J, Cavaco I, Yurdakok B, Mkrtchian S, Ingelman-Sundberg M. The ligands of
estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression. J
Pharmacol Exp Ther. 2011;338:302-9.
Sivertsson L, Edebert I, Porsmyr Palmertz M, Ingelman-Sundberg M, Neve EP.
Induced CYP3A4 Expression in Confluent Huh7 Hepatoma Cells as a Result of
22
292.
293.
294.
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
Decreased Cell Proliferation and Subsequent PXR Activation. Mol Pharmacol. 2013
Mar;83(3):659-70. doi: 10.1124/mol.112.082305. Epub 2012 Dec 21.
Eliasson E, Sim SC, Rane A, Ingelman-Sundberg M. Institutional profile: Karolinska
institutet. Pharmacogenomics. 2012 Dec;13(16):1887-91
Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual
differences in drug response. Clin Pharmacol Ther. 2012;92:727-36
Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drugmetabolizing enzymes: a recent update on clinical implications and endogenous
effects. Pharmacogenomics J. 2012 Oct 23.
Peyrot WJ, Middeldorp CM, Jansen R, Smit JH, de Geus EJ, Hottenga JJ, Willemsen
G, Vink JM, Virding S, Barragan I, Ingelman-Sundberg M, Sim SC, Boomsma DI,
Penninx BW. Strong effects of environmental factors on prevalence and course of
major depressive disorder are not moderated by 5-HTTLPR polymorphisms in a
large Dutch sample. J Affect Disord. 2012 Sep 26.
Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P,
Edler D. The expression of CYP2W1: a prognostic marker in colon cancer.
Anticancer Res. 2012;32:3869-74.
Sivertsson L, Synnergren J, Jensen J, Björquist P, Ingelman-Sundberg M. Hepatic
Differentiation and Maturation of Human Embryonic Stem Cells Cultured in a
Perfused Three-Dimensional Bioreactor. Stem Cells Dev. 2012 Nov 2. [Epub ahead
of print]
Kacevska M, Ivanov M, Ingelman-Sundberg M. Epigenetic-dependent regulation of
drug transport and metabolism: an update. Pharmacogenomics. 2012 ;13:1373-85.
Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, Ingelman-Sundberg M.
DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie.
2012;94:2338-44.
Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M,
Molden E, Eliasson E. UGT1A4*3 encodes significantly increased glucuronidation
of olanzapine in patients on maintenance treatment and in recombinant systems.
Clin Pharmacol Ther. 2012;92:221-7.
Neve EP, Nordling A, Andersson TB, Hellman U, Diczfalusy U, Johansson I,
Ingelman-Sundberg M. Amidoxime reductase system containing cytochrome b5
type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte
mitochondria. J Biol Chem. 2012;287:6307-17.
Lawson EB, Wu JC, Baldwin RM, Ingelman-Sundberg M, Rosenborg S, Yim DS, Yin
OQ, Capparelli EV, Ma JD. Omeprazole limited sampling strategies to predict area
under the concentration-time curve ratios: implications for cytochrome P450 2C19
and 3A phenotyping. Eur J Clin Pharmacol. 2012;68:407-13.
Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH,
Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a
pilot study: implications for propofol anesthesia. Eur J Clin Pharmacol.
2012;68:397-406.
Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, Uher R,
Gunasinghe C, Gray J, Campbell D, Hauser J, Maier W, Marusic A, Rietschel M,
Perez J, Giovannini C, Mors O, Mendlewicz J, McGuffin P, Farmer AE, IngelmanSundberg M, Craig IW, Aitchison KJ. CYP2C19 genotype predicts steady state
escitalopram concentration in GENDEP. J Psychopharmacol. 2012;26:398-407.
Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, Milani L. Insolution hybrid capture of bisulfite-converted DNA for targeted bisulfite
sequencing of 174 ADME genes. Nucleic Acids Res. 2013, 41(6):e72. doi:
10.1093/nar/gks1467. Epub 2013 Jan 15
23
306.
307.
308.
309.
310.
311.
312.
313.
314.
315.
316.
317.
318.
Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN.
Characterisation of Human Cytochrome P450s Involved in the Bioactivation of
Clozapine. Drug Metab Dispos. 2013 Mar;41(3):651-8. doi:
10.1124/dmd.112.050484. Epub 2013 Jan 7 2013 . [Epub ahead of print]
Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake
HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M Colon cancer-specific
cytochrome P450 2W1 converts duocarmycin analogues into potent tumor
cytotoxins. Clin Cancer Res. 2013 Apr 15. [Epub ahead of print]
Choong E, Loryan I, Lindqvist M, Nordling A, Elbouazzaoui S, van Schaik RH,
Johansson I, Jakobsson J, Ingelman-Sundberg M. Sex Difference in Formation of
Propofol Metabolites: A Replication Study. Basic Clin Pharmacol Toxicol. 2013 Mar
25. doi: 10.1111/bcpt.12070. [Epub ahead of print]
Sim SC, Ingelman-Sundberg M. Update on allele nomenclature for human
cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele)
Nomenclature Database. Methods Mol Biol. 2013;987:251-9. doi: 10.1007/978-162703-321-3_21.
Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F. 3D
Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies.
Toxicol Sci. 2013 May;133(1):67-78. doi: 10.1093/toxsci/kft021. Epub 2013 Feb 1.
Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, IngelmanSundberg M.High warfarin sensitivity in carriers of CYP2C9*35 is determined by
the impaired interaction with P450 oxidoreductase. Pharmacogenomics J. 2013
Dec 10. doi: 10.1038/tpj.2013.41. [Epub ahead of print]
Stenstedt K, Travica S, Guo J, Barragan I, Pors K, Patterson L, Edler D, Mkrtchian S,
Johansson I, Ingelman-Sundberg M. CYP2W1 polymorphism: functional aspects
and relation to risk for colorectal cancer. Pharmacogenomics. 2013
Oct;14(13):1615-22. doi: 10.2217/pgs.13.136.
Ivanov M, Kals M, Kacevska M, Barragan I, Kasuga K, Rane A, Metspalu A, Milani L,
Ingelman-Sundberg M. Ontogeny, distribution and potential roles of 5hydroxymethylcytosine in human liver function. Genome Biol. 2013 Aug
19;14(8):R83. [Epub ahead of print]
Neve EP, Artursson P, Ingelman-Sundberg M, Karlgren M. An integrated in vitro
model for simultaneous assessment of drug uptake, metabolism, and efflux. Mol
Pharm. 2013 Aug 5;10(8):3152-63. doi: 10.1021/mp400202d. Epub 2013 Jul 15.
Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M.
High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique
istribution of CYP2A6 Variant Alleles in Ethiopian Population.OMICS. 2013 Dec 31.
[Epub ahead of print]
Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L,
Osawa Y. Potential role of epigenetic mechanisms in the regulation of drug
metabolism and transport. Drug Metab Dispos. 2013 Oct;41(10):1725-31.
Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg
M.Decreased hippocampal volume and increased anxiety in a transgenic mouse
model expressing the human CYP2C19 gene. Mol Psychiatry. 2013 Jul 23. doi:
10.1038/mp.2013.89. [Epub ahead of print]
Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L,
Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M,
Ingelman-Sundberg M, Patterson LH, Pors K. Re-engineering of the duocarmycin
structural architecture enables bioprecursor development targeting CYP1A1 and
CYP2W1 for biological activity. J Med Chem. 2013 Aug 8;56(15):6273-7. doi:
10.1021/jm4000209. Epub 2013 Jul 26.
24
319.
320.
321.
322.
Stenstedt K, Hallstrom M, Lédel F, Ragnhammar P, Ingelman-Sundberg M,
Johansson I, Edler D. The expression of CYP2W1 in colorectal primary tumors,
corresponding lymph node metastases and liver metastases. Acta Oncol. 2014 Mar
13. [Epub ahead of print]
Persson A and Ingelman-Sundberg M: Pharmacogenomics of cytochrome P450
dependent metabolism of endogenous compounds: Implications for behavior,
psychopathology and treatment. J Pharmacogenomics Pharmacoproteomics 2014,
5:2 http://dx.doi.org/10.4172/2153-0645.1000127
Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of
importance for drug treatment. Trends Pharmacol Sci. 2014 Aug;35(8):384-396.
doi: 10.1016/j.tips.2014.05.004.
Holmgren G, Sjögren AK, Barragan I, Sabirsh A, Sartipy P, Synnergren J, Björquist P,
Ingelman-Sundberg M, Andersson TB, Edsbagge J. Long-term chronic toxicity
testing using human pluripotent stem cell-derived hepatocytes. Drug Metab
Dispos. 2014 Sep;42(9):1401-6. doi: 10.1124/dmd.114.059154.
25